Tacrine and rate of progression in Alzheimer's disease - Relation to ApoE allele genotype
2001 (English)In: Journal of neural transmission, ISSN 0300-9564, Vol. 108, no 4, 451-458 p.Article in journal (Refereed) Published
Today, cognitive impairment can be successfully treated with acetylcholine esterase inhibitors (AChE-I) in many, but not all, patients with Alzheimer's disease (AD). To investigate the relation between tacrine treatment, inheritance of ApoE e4 alleles, and rate of progression, the differences in MMSE and CIBIC scores (efficacy parameters) after 6 and 12 months of tacrine (an AChE-I) treatment were investigated in 145 AD patients. Of these, 84 were ApoE e4-positive (ApoE4) and 61 were ApoE e4-negative (ApoE2-3). No differences were found after 6 months of treatment, but after 12 months the CIBIC scores revealed that the ApoE4 patients had declined more than the ApoE2-3 patients (p < 0.05). No differences were found for the last 6 months of treatment. The results primarily suggest a faster rate of decline in the ApoE4 AD compared to the ApoE2-3, but may also reflect that ApoE e4 genotype inheritance is a negative predictor of treatment effect of tacrine in AD patients.
Place, publisher, year, edition, pages
2001. Vol. 108, no 4, 451-458 p.
Acetylcholine esterase, Alzheimer's disease, ApoE, CIBIC, MMSE, Tacrine, Treatment
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-47290DOI: 10.1007/s007020170066OAI: oai:DiVA.org:liu-47290DiVA: diva2:268186